Tillotts Pharma announced that the Medicines and Healthcare Products Regulatory Agency has approved a new indication for Entocort that includes treatment of patients with microscopic colitis, according to a press release.
Entocort is an anti-inflammatory agent and locally acting glucocorticosteroid that is already available in 40 countries for the treatment of mild-to-moderate ileocecal Crohn’s disease and ulcerative colitis.
Patients with microscopic colitis (MC) often experience abdominal pain, weight loss and other symptoms that impact their quality of life.
Although awareness about the disease and its subtypes — lymphocytic colitis (LC) and collagenous colitis (CC) — has risen over the years, misdiagnoses are still common, according to the press release.
This approval makes Entocort the first budesonide available for both LC and CC in the United Kingdom.
“MC is a chronic and disabling condition that can be particularly challenging to diagnose,” Robert Hofmann, MD, PhD, medical director for Tillotts said in the press release. “Proper diagnosis and regular follow-ups are important to offer a treatment that can improve the patient’s quality of life.”
Disclosures: Hofmann is employed by Tillotts.